Teikoku Enters into an Agreement with Altea Therapeutics for the Development, Manufacture, and Commercialization in Japan of a New Transdermal Therapy for Parkinson’s Disease

In furthering it’s strength in transdermal drug delivery, Teikoku signs an agreement with Altea Therapeutics to develop and commercialize a new patch therapy for managing Parkinson’s Disease, utilizing Altea Therapeutics’ PassPort technology.